ATAI News and Press, ATAI Life Sciences N.V. From 03/28/24

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durabl...

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 1...

University of Calgary scientists want to conduct a trial on the use of psilocybin as a treatment for alcohol use disorder (AUD). The trial will be carried out at the Hotchkiss Brain Institute and will include 128 individuals with alcohol use disorder. Each of the participants will undergo s...

Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...

2024-03-19 08:00:07 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – March 19, 2024 – The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in “magic mushrooms,” as a &#...

--News Direct-- atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component...

Experts predict that one of the key focuses for investors this year will be neuroscience and cancer-focused companies , with psychedelics being a priority within the neuroscience space. The specialists project that 2024 may be another year of significant investment in studying solid tumors and...

2024-03-07 11:29:12 ET More on Clearmind Medicine, Bright Minds, etc. Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMT VLS-01 is being developed as a rapid-acting and durable antidepressant for treatment resistant depress...

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at t...